Cancer continues to be a serious global health concern, with increasingly more cases each year requiring advanced treatments and medical advancements. Luckily, in India, the battle against cancer has shown some remarkable progress owing to the new therapies developed that enhance cancer patient outcomes.
AstraZeneca Pharma India Ltd has, in a remarkable move, received authorization from the Central Drugs Standard Control Organisation (CDSCO) to import and sell a cancer medication called Durvalumab in India.
This is the first step towards offering novel immunotherapy treatment options to Indian patients suffering from advanced stages of cancer, such as unresectable hepatocellular carcinoma (uHCC). Imfinzi, the brand name under which the drug is sold, has had positive outcomes when given with Tremelimumab, and has brought hope to many cancer patients.
Understanding Durvalumab and Its Role in Cancer Treatment
Durvalumab is a form of immunotherapy drug belonging to a class known as PD-L1 inhibitors. Its purpose is to strengthen the immunity so that it can work effectively against the cancer cells. Unlike chemotherapy, which attacks the cancer cells directly, Durvalumab has a more refined mechanism that allows the immune system to identify and attack the cancer cells.
The drug is used for managing several types of cancers, such as NSCLC and bladder cancer, and most recently has been approved for unresectable hepatocellular carcinoma (uHCC). The latter is the most prevalent form of liver cancer, and in its advanced stages, where it turns into a malignant tumour, the surgical option is no longer possible, and immunotherapy becomes essential.
Role of CDSCO in Regulating Pharmaceuticals in India
The government’s principal organ responsible for regulating drugs and medical devices is the Central Drugs Standard Control Organisation (CDSCO). It functions under the Directorate General of Health Services, Government of India, and its responsibility is to verify the safety, effectiveness, and quality of medical products in the country.
To register a foreign drug for sale in India, companies must first obtain authorization from CDSCO. This cumbersome procedure guarantees that imported medicine for use in India complies with the health and safety rules of the country. The approval of AstraZeneca’s Durvalumab (Imfinzi) is one case that underwent and passed through the scrutiny of regulatory review and assessment. Getting CDSCO import license is crucial.
Talk To Expert
AstraZeneca Pharma India gets CDSCO Approval to Import, Sell Cancer Treatment Medicine
(4.8)
Significance of This Approval for Indian Cancer Patients
The approval for Durvalumab for a new indication is a milestone in India’s fight against cancer. This is why this move is significant:
- Expanding Treatment Options for Liver Cancer Patients:
Liver cancer, also known as hepatocellular carcinoma (HCC), is one of the most deadly cancers around the globe. Patients diagnosed with unresectable HCC have limited options for treatment, and combining Durvalumab with Tremelimumab offers them a new, favourable therapy that increases survival and quality of life.
- Bridging the Gap Between Global and Indian Health Care:
Unlike the Western economies, where innovative drugs are made available far ahead of time, India suffers from a market and regulatory restriction. With the recent CDSCO approval, Indian patients will now have access to these known treatments and will receive similar standard care to that of developed healthcare systems.
- Augmenting India’s Immunotherapy Landscape:
Immunotherapy is revolutionizing cancer treatment with targeted and personalized therapies. Approval for Durvalumab consolidates India’s position in adopting modern oncology treatments and alignment with international trends towards immune-based therapies instead of conventional chemotherapy.
Durvalumab (Imfinzi) and Its Clinical Benefits
Imfinzi has demonstrated impressive clinical benefits in several studies. Its efficacy of Durvalumab has been proven in the following clinical benefits:
➢ Increased Rates of Survival: Imfinzi combined with Tremelimumab has proven to increase overall survival in patients suffering from unresectable liver cancer during clinical trials.
➢ Reduced Disease Progression: The disease is controlled due to the blockade of the PD-L1 immune checkpoint, which enables immune evasion by tumour cells.
➢ Greater Tolerance than Chemotherapy: Unlike standard cancer treatments, immunotherapy drugs such as Durvalumab have higher tolerance and lower side effects.
AstraZeneca’s Commitment to Cancer Care in India
AstraZeneca Pharma India Ltd has been striving continuously to introduce innovative cancer treatments to the country. It has a strong presence in oncology and has introduced a number of breakthrough therapies to Indian patients.
With approval for Durvalumab in unresectable HCC, AstraZeneca reinforces its dedication to making life-saving therapies more accessible. AstraZeneca’s dedication is not just to drug distribution and importation but to helping healthcare professionals with training and information to optimize the use of advanced therapies. CDSCO registration is an essential requirement for such ventures.
Challenges and Future Prospects
While this approval is a welcome step, there are still hurdles to making Durvalumab affordable and available to patients in India. Some important considerations include:
➢ Cost and Affordability:
Access to immunotherapy drugs is limited because of its cost, and so, it is out of reach for many cancer patients in India. AstraZeneca and the government will have to develop strategies such as patient support programs, insurance coverage, and cost negotiations to increase access to the treatment.
➢ Awareness among Patients and Oncologists:
The majority of Indian oncologists tend to rely on chemotherapy and radiation, as they are well-known treatment modalities. Greater education about the possibility of immunotherapy and who qualifies for it will be necessary for its wider adoption.
➢ Expanding Indications to Other Cancer Types:
Apart from the already approved indication of unresectable liver cancer, Durvalumab could also be tried in clinical studies and submitted to regulatory authorities for possible approval in breast, pancreatic, and gastric cancers.
Conclusion
The CDSCO approval for Durvalumab (Imfinzi) for a new indication in cancer is a big breakthrough in Indian healthcare. This comes as a relief to many cancer patients with very few treatment alternatives available for unresectable hepatocellular carcinoma.
Achieving this milestone for Astrazeneca shows how critical it is to bring global medical innovations to India for the patients to receive the best possible treatment. With the country accepting immunotherapy at a greater pace, there will need to be greater collaboration between pharma companies, healthcare providers, and drug regulators to ensure that advanced healthcare is both accessible and affordable.
The future of cancer treatment in India is transforming, and with Durvalumab, there is a further leap in cancer combat in the country.
To get expert assistance in securing CDSCO medical device import license, visit https://corpbiz.io/.
Frequently Asked Questions
What is Durvalumab (Imfinzi), and how does it work?
Durvalumab (Imfinzi) is an immunotherapy medication that is part of the class of drugs called PD-L1 inhibitors. Unlike chemotherapy, which targets cancer cells, Imfinzi and other PD-L1 inhibitors help the immune system identify and attack the cancer cells. PD-L1 inhibitors are showing positive results in treating numerous cancers, like non-small cell lung cancer (NSCLC), bladder cancer, as well as unresectable hepatocellular carcinoma (uHCC).
What changes in the cancer treatment landscape does CDSCO’s approval for Durvalumab imply in India?
With CDSCO (Central Drugs Standard Control Organisation) approval, AstraZeneca Pharma India can now import and market Durvalumab (Imfinzi) in India. This approval is an addition to the medications available to Indian patients suffering from unresectable hepatocellular carcinoma (uHCC), which has limited treatment options available.
What is the impact of Durvalumab therapies on cancer patients compared to traditional chemotherapy?
Durvalumab has multiple benefits over chemotherapy, such as:
– Increased survival with Tremelimumab combination therapy.
– Decreased disease progression with the PD-L1 immune checkpoint blockade.
– Better tolerance of the medication and fewer side effects than chemotherapy.How does CDSCO function in the approval and regulation of pharmaceuticals in India?
The CDSCO is the apex authority in India responsible for the pharmaceutical and medical devices industry. It ensures that medicines imported in the country are safe for the patients and like any other drug in India, are of required health and safety standards.
Why is the approval of Durvalumab significant in the treatment of cancer in India?
The approval is significant because:
– Liver cancer patients will have an additional treatment option
– It helps integrate Indian healthcare with the global advanced therapies available.
– It changes the treatment paradigm to focus on targeted therapies and enhances immunotherapy in India.What are the barriers to the effective implementation of Durvalumab in the Indian market?
Even with the approval, some barriers include:
– Patients have limited access due to the high cost.
– There’s a vacuum of knowledge among oncologists and patients regarding the benefits of immunotherapy.
– It involves broadening the scope of the drug to other cancers through clinical research and obtaining relevant approvals in India.What are the responsibilities of AstraZeneca Pharma India with respect to the cancer care business?
AstraZeneca Pharma India has an active role in using pioneering cancer therapies in the country. Besides bringing and marketing the drug, the company is also involved in education, and advocacy, provides training for healthcare professionals on the use of the drug, and collaborates with stakeholders to improve cancer treatment accessibility.
Read our blogs: CDSCO’s National Single Window System Portal
